Oppenheimer Believes Chemed (CHE) Still Has Room to Grow


In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Chemed (CHE). The company’s shares closed yesterday at $328.77, close to its 52-week high of $335.99.

According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 14.4% and a 66.4% success rate. Wiederhorn covers the Services sector, focusing on stocks such as Cross Country Healthcare, Addus Homecare Corp, and Community Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chemed with a $318 average price target.

See today’s analyst top recommended stocks >>

Based on Chemed’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $54.33 million. In comparison, last year the company had a net profit of $54.55 million.

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.